Clinical Trials

This study will investigate the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.

The overall goal is to determine the safety, feasibility, and preliminary efficacy of administering oral LT3 therapy in the study population of participants with heart failure.

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Do you have heart failure with reduced ejection fraction and thyroid problems? This study will test whether hormone therapy with liothyronine is safe and effective for treating people who have heart failure with reduced ejection fraction and low triiothyronine (T3) syndrome. Low T3 syndrome is a type of thyroid hormone that helps control many functions of your body. To participate in this study, you must be at least 18 years old and diagnosed with heart failure with reduced ejection fraction. This study is located in Philadelphia, Pennsylvania.

Do you have heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD)? This study is testing the effectiveness of thyroid hormone therapy with a medicine called liothyronine (LT3) in individuals HFrEF. To participate in this study, you must be at least 18 years old and have Class I, II, or III heart failure. This study takes place in Philadelphia, Pennsylvania.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.